William J Chase bought $1.0M of NTLA
director at Intellia Therapeutics, Inc.. 100,000 shares at an average of $10.03, traded Aug 20, 2025, filed Aug 22, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.0M at market
- +10Relative to holdingsHoldings up 288%
- +8Price context55% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +48.2%, 3m -22.0%, 6m +20.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-110979, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 20, 2025 | POpen-market purchase Common Stock | +100,000 | $10.03 | $1.0M | 134,693 | Aug 22, 2025 |
Related signals
Other insiders at Intellia Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | NTLAsell Intellia Therapeutics, Inc. | Michael P Dube VP, Chief Accounting Officer | $23k 1,864 shares | -3% | |
| 23Weak | Intellia Therapeutics, Inc. | James Basta EVP, General Counsel | $17k 1,211 shares | -1% | |
| 23Weak | Intellia Therapeutics, Inc. | Eliana Clark EVP, Chief Technical Officer | $8,364 607 shares | -1% | |
| 40Moderate | Intellia Therapeutics, Inc. | James Basta EVP, General Counsel | $96k 10,397 shares | -9% | |
| 39Weak | Intellia Therapeutics, Inc. | Eliana Clark EVP, Chief Technical Officer | $88k 9,515 shares | -10% | |
| 58Moderate | NTLAbuy Intellia Therapeutics, Inc. | Fred E Cohen director | $1.4M 150,000 shares | +261% | |
| 35Weak | Intellia Therapeutics, Inc. | Michael P Dube VP, Chief Accounting Officer | $28k 2,989 shares | -5% | |
| 44Moderate | Intellia Therapeutics, Inc. | Edward J Dulac III EVP, Chief Financial Officer | $59k 6,379 shares | -6% | |
| 40Moderate | Intellia Therapeutics, Inc. | David Lebwohl EVP, Chief Medical Officer | $110k 11,903 shares | -9% | |
| 39Weak | Intellia Therapeutics, Inc. | Birgit C Schultes EVP, Chief Scientific Officer | $78k 8,508 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.